Gossamer Bio, Inc. (GOSS)
$9.31-5.77%Close
SELLCRISIS · day 23
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.2B
- Beta
- 2.00
- P/E (TTM)
- -0.24
- Short % float
- 0.69%
- Days to cover
- 3.5
- SI change
- +30.5%
- 1W
- -13.07%
- 1M
- -18.26%
- vs SPY 1W
- -14.23%
- vs SPY 1M
- -21.25%
Industry peers
FMP comparable companies · ranked by market cap
- RAPTRAPT Therapeutics, Inc.$1.6B$58.01
- KALVKalVista Pharmaceuticals, Inc.$1.4B$27.00
- VTYXVentyx Biosciences, Inc.$1.0B$14.00
- RIGLBUYRigel Pharmaceuticals, Inc.$888MBULLQ 9$47.99+0.74%
- CRVSSELLCorvus Pharmaceuticals, Inc.$875MCRISISQ 13$10.41+3.04%
- LXRXSELLLexicon Pharmaceuticals, Inc.$782MCRISISQ 5$1.76-4.55%
- OLMASELLOlema Pharmaceuticals, Inc.$694MCRISISQ -1$7.94+0.00%
- FDMTSELL4D Molecular Therapeutics, Inc.$658MCRISISQ 4$12.59+4.96%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on GOSS?
- LOPJLB’s latest quantitative signal on Gossamer Bio, Inc. (GOSS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is GOSS in?
- Gossamer Bio, Inc. (GOSS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Gossamer Bio, Inc. (GOSS) do?
- Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in P…